What we're reading, May 27, 2016: treatment for pregnant women is often based on guesswork since few drugs are ever tested on them; a new superbug in the US is resistant to even the antibiotic of last resort; and how small physician practices can adapt to new payment models.
With most drugs never tested on pregnant women, treatment is often based on guesswork. According to a report in ProPublica, the desire to protect the fetus has deterred scientists and drug makers from studying expectant mothers, which means almost every drug prescribed during pregnancy in the US is considered “off label.” However, as many as 9 in 10 pregnant women use medications and yet ob/gyns often find themselves in the dark about basic best practices.
A new superbug has arrived in the United States that is resistant to antibiotics of last resort. The deadly antibiotic-resistant strain, which has already been identified in China, Europe, and elsewhere, could mean the end of antibiotics, according to The Washington Post. Scientists and public health officials warn that if resistant bacteria spread, minor infections could become life threatening, pneumonia could become more difficult to treat, and even routine operations could become deadly.
In a post on The Commonwealth Fund’s website, David Blumenthal, MD, and David Squires consider how small physician practices can adjust to new payment models in healthcare. Reforms such as the Medicare Access and CHIP Reauthorization Act seem to favor larger practices over small or solo practices. However, Blumenthal and Squires outline ways in which small practices can transition to the new payment paradigm, such as improved health information technology and physician networks.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More